Welcure Drugs & Pharmaceuticals share price
BSE: 524661Pharmaceuticals & BiotechnologySmall Cap
Welcure Drugs & Pharmaceuticals ltd · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1994
Last close ₹0.19₹0.00 (0.00%)
Share price at the BSE close on 28 Oct 2026. Previous close ₹0.19.
28 Oct: open ₹0.19, high ₹0.19, low ₹0.18
52-week range of traded prices to 28 Oct 2026
₹0.17Low, 23 Oct 2026₹0.64High, 13 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹23 Cr3,646th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 15,74,324
Results
Standalone; ₹ crore.Welcure Drugs & Pharmaceuticals quarterly results
Quarter to Mar 2026, against the quarter before
- RevenueRevenue. Under it, revenue in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.00 CrQuarter to Dec 2025: ₹0.00 Cr
- Net profit
- −₹50 Cr
Revenue by quarter
Peak revenue ₹300 Cr, quarter to Jun 2025; lowest ₹0.00 Cr, quarter to Jun 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in the quarter to Mar 2026, −₹50 CrA loss in 2 of the 8 quarters shown
| ₹ crore | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 25 | 9 | 21 | 300 | 66 | 0 | 0 |
| Net profit | 0 | 2 | 0 | 3 | 23 | 9 | 1 | −50 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary | – | 7.5% | 4.7% | 12.0% | 7.8% | 13.0% | – | – |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026
- Revenue
- ₹366 Cr
- Net profit
- −₹5.49 Cr
- Net margin
- −1.5%
Revenue by year
Peak revenue ₹366 Cr, year to Mar 2026; lowest ₹0.00 Cr, year to Mar 2023
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 9 years with results on record
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 366 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | −5 |
| Net margin | 31.1% | −38.0% | 4.9% | −11.5% | 41.3% | 22.5% | – | – | – | −1.5% |
Standalone. Years to March. The latest is shaded. No results on record for the year to Mar 2025.
Business segments
One segment, Agriculture, carries all the revenue in the year to Mar 2026.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −71.0% | – | – | 0.0% |
| 3 years | −13.1% | – | – | 0.0% |
| 5 years | +7.0% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Welcure Drugs & Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Welcure Drugs & Pharmaceuticals in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.Healthcare companies
Welcure Drugs & Pharmaceuticals is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Medi CapsMEDICAPQ | 31 | – | 0.28 | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Goldline PharmaceuticalGLPL | 29 | 7.11 | 2.05 | – | – | 28.9% | – | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 6.98 | – | – | – | 22.4% | – | 0.00% |
 Bacil PharmaBACPHAR | 28 | – | 1.10 | – | – | – | −0.7% | 0.00% |
 Walpar NutritionsWALPAR | 23 | 9.49 | 1.24 | +9.8% | −42.7% | 14.0% | – | 0.00% |
 Lasa SupergenericsLASA | 23 | – | 0.47 | −95.2% | – | −24.8% | −24.8% | 0.00% |
 Ishita Drugs & IndustriesISHITADR | 22 | 31.58 | 1.93 | −28.6% | −31.0% | 6.3% | 5.3% | 0.00% |
 Centuple GlobalCENTUPLE | 20 | 16.49 | 9.86 | +4,540.6% | +1,281.3% | 94.1% | 22.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Welcure Drugs & Pharmaceuticals announcements
Jul 2026
Jun 2026
19 Jun · Board meeting
Meeting on 19 Jun 202619 Jun · Management
May 2026
Welcure Drugs & Pharmaceuticals annual report, year to Mar 2025
Welcure Drugs & Pharmaceuticals share price by year
Each calendar year to 2025.Welcure Drugs & Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 0.42 | −60.4% | 1.44 | 0.41 |
| 2024 | 1.06 | +203.1% | 1.37 | 0.34 |
| 2023 | 0.35 | −31.0% | 0.51 | 0.32 |
| 2022 | 0.51 | −26.2% | 1.05 | 0.42 |
| 2021 | 0.69 | +240.5% | 1.05 | 0.17 |
| 2020 | 0.20 | +353.1% | 0.21 | 0.03 |
| 2019 | 0.04 | −5.8% | 0.06 | 0.04 |
| 2018 | 0.05 | −53.2% | 0.13 | 0.05 |
| 2017 | 0.10 | −70.4% | 0.42 | 0.08 |
| 2016 | 0.34 | +47.6% | 0.38 | 0.10 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 0.18 | 0.19 | 0.18 | 0.19 | 0.18 | 20,86,507 |
| 26 Oct 2026 | 0.18 | 0.19 | 0.18 | 0.18 | 0.18 | 19,76,853 |
| 23 Oct 2026 | 0.19 | 0.20 | 0.17 | 0.18 | 0.18 | 76,25,873 |
| 22 Oct 2026 | 0.19 | 0.20 | 0.19 | 0.20 | 0.19 | 18,14,143 |
| 21 Oct 2026 | 0.20 | 0.21 | 0.19 | 0.19 | 0.20 | 58,42,866 |
| 19 Oct 2026 | 0.20 | 0.21 | 0.19 | 0.19 | 0.20 | 25,11,224 |
| 16 Oct 2026 | 0.20 | 0.21 | 0.19 | 0.20 | 0.20 | 35,63,086 |
| 15 Oct 2026 | 0.20 | 0.21 | 0.20 | 0.20 | 0.20 | 45,20,170 |
| 14 Oct 2026 | 0.21 | 0.21 | 0.20 | 0.20 | 0.20 | 33,98,787 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 16 Oct 2025 | Bonus | 0.9091 | Holders received 1 bonus share for every 10 held. |
| 16 Oct 2025 | Split | 0.1000 | Each share became 10. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- BSE code
- 524661
- ISIN
- INE331C01025
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.welcuredrugs.com
- CIN
- L24232DL1996PLC227773
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1996
- Registered office
- 107 / 22, Gali No-3, East Azad Nagar, Delhi 110051, Delhi
- Share registrar
- Skyline Financial Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments